On this page
Familial chylomicronaemia syndrome
This autosomal recessive condition prevents the body from breaking down fat-rich particles called chylomicrons, leading to extremely high triglyceride concentrations. Affected individuals experience recurrent abdominal pain, pancreatitis episodes, and distinctive physical signs, requiring lifelong dietary management.
Available at Jeen Health
Clinical tests that include this
Overview
Familial chylomicronaemia syndrome affects approximately one person per million worldwide, making it an exceptionally rare metabolic disorder. The condition arises when genetic changes prevent normal breakdown of dietary fats in the bloodstream, causing triglyceride levels to rise dramatically-often exceeding 10 mmol/L and sometimes reaching values above 50 mmol/L. These extreme elevations begin in early childhood and persist throughout life.
The hallmark clinical feature is recurrent acute pancreatitis, a painful and potentially life-threatening inflammation of the pancreas triggered by the accumulation of chylomicrons. Many affected individuals experience their first episode during childhood, though the age of onset varies. Between acute episodes, people often develop chronic abdominal discomfort and may notice creamy-appearing blood when samples are taken. Recognition of this rare condition is important because standard triglyceride-lowering medications prove largely ineffective, and management centres on strict dietary fat restriction.
Symptoms & clinical features
The most serious manifestation is recurrent acute pancreatitis, presenting with severe upper abdominal pain that may radiate to the back, nausea, and vomiting. Episodes can occur unpredictably and may require hospital admission for supportive care. Even between acute attacks, many affected individuals report persistent or intermittent abdominal discomfort.
Physical examination may reveal eruptive xanthomas-small yellowish skin bumps caused by fat deposits-particularly on the buttocks, back, and extensor surfaces of the limbs. Lipaemia retinalis, a creamy appearance of retinal blood vessels visible during eye examination, occurs when triglyceride levels are exceptionally high. The liver and spleen often become enlarged due to accumulation of fat-laden cells. Some people notice their blood has a milky appearance when collected for testing, reflecting the high concentration of chylomicrons.
Video: Genetics 101
Affected organs
The pancreas bears the greatest burden, with repeated inflammatory episodes potentially leading to chronic pancreatitis, pancreatic insufficiency, and diabetes mellitus over time. The accumulation of chylomicrons creates a direct toxic effect on pancreatic tissue. The liver frequently enlarges as it attempts to process excess lipids, though severe liver dysfunction is uncommon. The spleen may also enlarge, and fat deposits can affect multiple organ systems including the skin and eyes. Unlike other forms of severe hypertriglyceridaemia, familial chylomicronaemia syndrome does not substantially increase risk of cardiovascular disease, as the accumulated particles differ from those that promote atherosclerosis.
Risks & severity
Severity varies among affected individuals, but all face lifelong risk of acute pancreatitis. The frequency of attacks ranges from several episodes per year to occasional events triggered by dietary indiscretion or metabolic stress such as pregnancy or infection. Acute pancreatitis carries risks of serious complications including pancreatic necrosis, pseudocyst formation, and multi-organ failure in severe cases.
Long-term complications reflect cumulative pancreatic damage. Chronic pancreatitis may develop, causing persistent pain and digestive problems. Pancreatic endocrine function can deteriorate, leading to diabetes mellitus requiring insulin therapy. Exocrine insufficiency may necessitate pancreatic enzyme replacement. Adherence to an extremely low-fat diet substantially reduces pancreatitis risk, though even with strict management, some individuals continue experiencing episodes. Pregnancy poses particular challenges, as physiological triglyceride elevation during the third trimester compounds the underlying disorder.
Genetic causes
Familial chylomicronaemia syndrome results from pathogenic variants in genes essential for breaking down triglyceride-rich lipoproteins. The LPL gene encodes lipoprotein lipase, the key enzyme that hydrolyses triglycerides within chylomicrons and very-low-density lipoproteins at the surface of blood vessels. Variants disrupting LPL function account for the majority of cases.
Several other genes encode proteins that enable lipoprotein lipase activity. APOC2 produces apolipoprotein C-II, a cofactor required to activate lipoprotein lipase. GPIHBP1 encodes a protein that anchors lipoprotein lipase to the capillary endothelium, positioning the enzyme where it can access circulating lipoproteins. LMF1 produces lipase maturation factor 1, a chaperone protein necessary for proper folding and transport of lipoprotein lipase within cells. Pathogenic variants in any of these genes prevent effective triglyceride breakdown, causing chylomicrons to accumulate in the circulation after fat-containing meals.
- APOC2 apolipoprotein C2
- GPIHBP1 glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1
- LMF1 lipase maturation factor 1
- LPL lipoprotein lipaseThe LPL gene provides instructions for creating lipoprotein lipase, an enzyme crucial for the breakdown of fats (triglycerides) transported in the bloodstream.
Inheritance pattern
This condition follows an autosomal recessive inheritance pattern. Affected individuals carry pathogenic variants in both copies of one of the causative genes-one inherited from each parent. Parents of an affected person are typically carriers, possessing one altered copy and one functioning copy. Carriers generally remain healthy, though some may have mildly elevated triglyceride levels.
When both parents are carriers of variants in the same gene, each pregnancy carries a 25 per cent chance of producing an affected child, a 50 per cent chance of a carrier child, and a 25 per cent chance of a child with two normal gene copies. Siblings of affected individuals have a two-thirds probability of being carriers if unaffected. Genetic counselling helps families understand these probabilities and discuss reproductive options, including carrier testing for at-risk relatives and prenatal or preimplantation genetic diagnosis where appropriate.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis typically begins with recognition of extremely elevated triglyceride levels-often discovered during investigation of abdominal pain or routine blood tests showing milky serum. Fasting triglyceride concentrations persistently exceeding 10 mmol/L in a child or young adult raise strong suspicion. Demonstration that the hypertriglyceridaemia persists despite a very low-fat diet helps distinguish familial chylomicronaemia syndrome from multifactorial hypertriglyceridaemia.
Genetic testing confirms the diagnosis by identifying pathogenic variants in LPL, APOC2, GPIHBP1, or LMF1. Within the NHS Genomic Medicine Service, familial chylomicronaemia syndrome testing is available through the Familial hypercholesterolaemia or familial dyslipidaemia pathway (R446 and related codes). Referral typically comes from lipid specialists, clinical geneticists, or gastroenterologists familiar with the condition. Post-test genetic counselling discusses implications for the patient and family members, including carrier testing options for relatives.
Management & lifestyle
Management centres on rigorous dietary fat restriction, typically limiting fat intake to 15-20 grams daily or approximately 10-15 per cent of total calories. This extremely low-fat diet requires specialist dietetic support to ensure nutritional adequacy whilst minimising chylomicron formation. Medium-chain triglycerides, which bypass the chylomicron pathway, may be used as an alternative fat source. Supplementation with fat-soluble vitamins (A, D, E, K) is often necessary.
Standard lipid-lowering medications including statins and fibrates have limited efficacy in familial chylomicronaemia syndrome. Omega-3 fatty acid supplements may provide modest benefit in some cases. During pregnancy, particularly close monitoring is required as physiological changes further elevate triglyceride levels; some women require hospital admission for supervised dietary management. Avoidance of secondary triggers such as alcohol, uncontrolled diabetes, and certain medications (thiazides, beta-blockers, oestrogens) helps reduce pancreatitis risk. Patients require ongoing follow-up with specialist lipid services and access to emergency care protocols for acute pancreatitis episodes.
UK care pathway
Within the NHS, individuals with suspected familial chylomicronaemia syndrome are typically referred to specialist lipid clinics, often attached to cardiology or endocrinology services. These clinics can access genetic testing through NHS Genomic Medicine Service pathways for familial dyslipidaemia, using PanelApp panels that include the relevant causative genes. Clinical genetics services provide genetic counselling both before and after testing, discussing inheritance patterns and implications for family members.
Ongoing care involves coordination between lipid specialists, dietitians experienced in metabolic disorders, and gastroenterology services for pancreatitis management. Many patients benefit from individualised emergency management plans shared with local hospitals. Access to genetic counsellors supports reproductive decision-making and cascade testing of at-risk relatives, which can identify carriers and provide reproductive information before they start families.
Frequently asked questions
Can people with familial chylomicronaemia syndrome eat a normal diet?
No, affected individuals require an extremely low-fat diet throughout life, typically limiting fat to 15-20 grams daily. This restriction is essential to prevent dangerous triglyceride elevations and reduce pancreatitis risk. Specialist dietetic support helps ensure nutritional adequacy whilst maintaining fat restriction.
Will standard cholesterol medications help control triglycerides in this condition?
Unfortunately, medications that work well for common forms of high triglycerides-including fibrates and statins-have minimal effect in familial chylomicronaemia syndrome. Dietary management remains the cornerstone of treatment, though some patients may derive modest benefit from high-dose omega-3 fatty acids.
What are the chances of passing this condition to children?
If you have familial chylomicronaemia syndrome, each of your children will definitely be a carrier. Whether they develop the condition depends on your partner's carrier status. If your partner is a carrier of variants in the same gene (uncommon unless you are related or from the same small community), there is a 50 per cent chance each child will be affected. Genetic counselling can clarify individual family risks.
How often do people with this condition experience pancreatitis attacks?
Attack frequency varies widely between individuals and depends heavily on dietary adherence. With strict fat restriction, some people go years between episodes, whilst others experience attacks several times yearly despite careful management. Metabolic stresses such as pregnancy, infection, or alcohol use can trigger episodes even in those usually well controlled.
References
- Moulin P, Dufour R, Averna M. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". Atherosclerosis. 2018. PMID: 29980054
- Wierzbicki AS, Kim EJ, Esan O. Hypertriglyceridaemia: an update. Journal of clinical pathology. 2022. PMID: 35710321
- Navarro Hermoso A, Valdivielso P. Treatment of chylomicronemia. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis. 2021. PMID: 34006359
- Hegele RA. APOC3 Interference for Familial Chylomicronaemia Syndrome. TouchREVIEWS in endocrinology. 2022. PMID: 36694895
- Bashir B, Ho JH, Downie P. Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome-Causes, Clinical Presentation, and Therapeutic Options. Metabolites. 2023. PMID: 37233662
- Cefalù AB, D'Erasmo L, Iannuzzo G. Efficacy and safety of lomitapide in familial chylomicronaemia syndrome. Atherosclerosis. 2022. PMID: 36152419
- Syed YY. Olezarsen: First Approval. Drugs. 2025. PMID: 40074987
- Wierzbicki AS, Reynolds TM. Genetic risk scores in lipid disorders. Current opinion in cardiology. 2019. PMID: 31169601